Presentation Material for information Meeting (Q2 YTD/FY2026)
Filed with TSE · · 43 pages · English
Summary by 6ix AI
The report highlights strong revenue growth and significant progress in its pipeline, leading to an upward revision of the full-year forecast. Key brands such as PADCEV and IZERVAY have shown robust performance, contributing to the overall financial success. The document also outlines advancements in clinical programs and strategic brand management initiatives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Astellas Pharma's latest callAstellas Pharma (Tokyo:4503) Q4 2025 Earnings Call · Replay · Apr 27Read the transcript of Astellas Pharma (Tokyo:4503) Q4 2025 Earnings CallIn the deck
Earlier from Astellas Pharma
- Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
- Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
- Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
- Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines
- Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Follow Astellas Pharma into a list and get an email when it puts out news.
Follow Astellas Pharma